Cingulate (CING) vs Coya Therapeutics (COYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed Coya Therapeutics (COYA) over the past year, gaining 27.8% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $67.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | COYA |
|---|---|---|
| Share price | $4.51 | $2.95 |
| Market cap | $67.48M | $69.20M |
| 1-day change | -14.26% | -1.01% |
| YTD return | +3.92% | -49.14% |
| 1-year return | +27.76% | -50.67% |
| EPS (TTM) | $-2.67 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $7.95M |
| Revenue growth (YoY) | — | +123.57% |
| Net income (latest FY) | $-22.45M | $-21.23M |
| Operating margin | — | -283.87% |
| Net margin | — | -267.14% |
| 52-week high | $11.89 | $6.62 |
| 52-week low | $3.16 | $2.72 |
| Distance from 52-week high | -62.07% | -55.44% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +370.07% | +415.59% |
| Average volume | 178.82K | 149.18K |
| Shares outstanding | 14.96M | 23.46M |
| Employees | 14 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed COYA by 78.4 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CING vs COYA FAQ
Which is bigger, Cingulate or Coya Therapeutics?
Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $67.48M for Cingulate (CING).
Which stock has performed better over the past year, CING or COYA?
CING returned +27.76% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Coya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.